ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,769.00
0.41%
S&P ASX All Technology
3,068.30
0.93%
Brent Oil
78.26
1.49%
US Dollar vs AUD
1.50453
-0.01%
Bitcoin
71,304.25
0.96%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX

argenx (ARGX)

argenx SE
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARGX
DateTimeSourceHeadlineSymbolCompany
04/06/202415:00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
09/05/202421:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
09/05/202415:00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
08/05/202420:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
08/05/202407:30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
07/05/202415:00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
02/05/202415:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
16/04/202415:00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseNASDAQ:ARGXargenx SE
27/03/202417:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseNASDAQ:ARGXargenx SE
27/03/202407:00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024NASDAQ:ARGXargenx SE
26/03/202417:00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
08/03/202422:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
08/03/202408:01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingNASDAQ:ARGXargenx SE
01/03/202408:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
29/02/202417:00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
26/02/202417:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
22/02/202417:00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024NASDAQ:ARGXargenx SE
20/02/202422:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
20/02/202417:00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
18/01/202422:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
18/01/202417:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
08/01/202422:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
08/01/202417:00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesNASDAQ:ARGXargenx SE
02/01/202417:00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
21/12/202304:37Dow Jones NewsArgenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data TalkNASDAQ:ARGXargenx SE
20/12/202322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
20/12/202317:00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusNASDAQ:ARGXargenx SE
29/11/202303:16Dow Jones NewsArgenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data TalkNASDAQ:ARGXargenx SE
28/11/202323:03Dow Jones NewsArgenx Shares Down After Vyvgart Study Misses Primary EndpointNASDAQ:ARGXargenx SE
28/11/202322:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Your Recent History

TG
AXA
Axa
MRTX
MBTCBTC
Minibitcoin
LSE
WTI2
2x Long Wti Oil
TG
JCSA
JPMorgan ETFS Ireland ICAV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved